Lacto-N-neotetraose

Lacto-N-neotetraose (LNnT), an endogenous metabolite, inhibits TNF-α-induced IL-8 secretion in immature epithelial cells, exhibits anti-inflammatory activity, and enhances wound closure [1] [2] [4].

Lacto-N-fucopentaose I is a milk oligosaccharide.

Lacto-N-difucohexaose I (LNDFH I), a connecting agent, may facilitate the attachment of Lewis b sugar chain-bearing oligosaccharides to water-insoluble polysaccharides [1].

Lacto-N-triose II, a core structural unit of human milk oligosaccharides (HMOs), possesses nutraceutical potentials and is utilized in the synthesis of complex HMOs [1].

Lacto-N-fucopentaose V (LNFP V), a novel pentasaccharide, is an oligosaccharide identified in human milk and various biofluids [1].

Lacto-N-biose I, also known as Galβ1-3GlcNAc, is a naturally occurring metabolite that serves as a substrate for the α1,2-fucosyltransferase enzyme derived from Helicobacter pylori[1].

Lacto-N-difucohexaose II (LNDFH II), an oligosaccharide found in human milk, plays a crucial role in infant health [1].

Lacto-N-neodifucohexaose II (Compd 9), a derivative of a principal human milk tetrasaccharide [1], functions as a click chemistry reagent featuring an Azide group. This enables it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) with alkyne-bearing molecules. Additionally, it can engage in strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing DBCO or BCN groups.

Lacto-N-fucopentaose II (LNFP II), a sialyl-Lewis hapten of the human Lewis blood group determinant, serves as a monosialo-ganglioside/glycolipid and sialyl derivative, CA 19-9. It is recognized as a molecular tumor marker (TM) for biliopancreatic malignancy [1].